TY - JOUR
T1 - Rituximab monotherapy for remission induction of proliferative lupus nephritis flares
T2 - Description of 3 cases
AU - Moroni, Gabriella
AU - Gallelli, Beniamina
AU - Banfi, Giovanni
AU - Leoni, Antonio
AU - Messa, Piergiorgio
PY - 2010/5
Y1 - 2010/5
N2 - Background: The efficacy and safety of rituximab when not associated with other immunosuppressive therapy in induction of remission of proliferative lupus nephritis (PLN) has not until now been proven. Methods: We report on 3 patients with PLN (class IV), 1 with a nephritic flare and 2 with a proteinuric flare (all with nephrotic syndrome (NS)) treated with 3 intravenous methylprednisolone pulses for 3 consecutive days and with rituximab at day 3 and day 18 associated with oral prednisone. At the beginning of the fourth month of therapy, mycophenolate mofetil was combined with prednisone. Results: Three months after the beginning of therapy, renal function improved in the patient with the nephritic flare, and proteinuria fell to within the non-nephrotic range in all 3 patients. At the end of a follow-up of 24 months, the patient with the nephritic flare had normal renal function (serum creatinine from 1.7 to 1 mg/dL) and mild proteinuria (from 6 to 0.7 g/24 hours). The second patient was in complete remission (proteinuria from 5 to 0.127 g/24 hours) 27 months after the beginning of therapy. In the last patient, followed for 10 months, mild proteinuria persisted (from 6.6 to 0.7 g/24 hours). The therapy was well tolerated by all patients. No adverse effects occurred during the follow-up. Conclusion: Although our results must be confirmed by larger prospective studies, rituximab associated with methylprednisolone pulses without any other concomitant immunosuppressive drug seems to be effective and safe for induction therapy of severe flares of PLN.
AB - Background: The efficacy and safety of rituximab when not associated with other immunosuppressive therapy in induction of remission of proliferative lupus nephritis (PLN) has not until now been proven. Methods: We report on 3 patients with PLN (class IV), 1 with a nephritic flare and 2 with a proteinuric flare (all with nephrotic syndrome (NS)) treated with 3 intravenous methylprednisolone pulses for 3 consecutive days and with rituximab at day 3 and day 18 associated with oral prednisone. At the beginning of the fourth month of therapy, mycophenolate mofetil was combined with prednisone. Results: Three months after the beginning of therapy, renal function improved in the patient with the nephritic flare, and proteinuria fell to within the non-nephrotic range in all 3 patients. At the end of a follow-up of 24 months, the patient with the nephritic flare had normal renal function (serum creatinine from 1.7 to 1 mg/dL) and mild proteinuria (from 6 to 0.7 g/24 hours). The second patient was in complete remission (proteinuria from 5 to 0.127 g/24 hours) 27 months after the beginning of therapy. In the last patient, followed for 10 months, mild proteinuria persisted (from 6.6 to 0.7 g/24 hours). The therapy was well tolerated by all patients. No adverse effects occurred during the follow-up. Conclusion: Although our results must be confirmed by larger prospective studies, rituximab associated with methylprednisolone pulses without any other concomitant immunosuppressive drug seems to be effective and safe for induction therapy of severe flares of PLN.
KW - Proliferative lupus nephritis
KW - Rituximab therapy
UR - http://www.scopus.com/inward/record.url?scp=77951748096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951748096&partnerID=8YFLogxK
M3 - Article
C2 - 20383866
AN - SCOPUS:77951748096
VL - 23
SP - 357
EP - 361
JO - Journal of Nephrology
JF - Journal of Nephrology
SN - 1121-8428
IS - 3
ER -